Analysis of risk factors for fatty liver disease in a single-center study

Abstract

Abstract: Objective To investigate the epidemiological characteristics and risk factors of fatty liver disease(FLD) using cross-sectional data. Methods A total of 18 921 examinees at the First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine from January 2024 to December 2024 were enrolled. Participants were divided into a FLD group (n=5 083) and a non-FLD group (n=13 838) based on imaging findings. Clinical baseline data, laboratory results, and auxiliary examination results were collected and analyzed. Logistic regression was used to identify risk factors for fatty liver disease. Results The detection rate of FLD was 26.86%, with a higher prevalence in females (n=2 728, 27.24%) than males (n=2 355, 26.45%). Compared to the non-FLD group, the FLD group showed statistically significant differences (P<0.05) in TG, HDL-C, WBC, RBC, PLT, ALC, AMC, TyG, SIRI and AISI. Binary logistic regression analysis identified TyG (OR=1.07,95%CI:1.02~1.122,P<0.001) and AISI (OR=1.003,95%CI:1.002~1.004,P<0.001) as independent risk factors for FLD. Conversely, systemic immune-inflammation index SII (OR=0.998,95%CI:0.998~0.999) and SIRI (OR=0.618,95%CI:0.525~0.727) were protective factors. For every 1-unit increase in TyG, the detection rate of fatty liver increases by 7.0%. For every 1-unit increase in AISI, the detection rate of fatty liver increases by 0.3%. Conclusion TyG and AISI are risk factors for the development of fatty liver, while SII and SIRI are protective factors.

Key words: Fatty liver disease, TyG, AISI, SII, SIRI

DENG Fei-die, WANG Guang-fu, YANG Yang, WANG Zi-ming. Analysis of risk factors for fatty liver disease in a single-center study[J]. Chinese Hepatolgy, 2026, 31(4): 565-568.

References

[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018,34(5): 947-957.
[2] Younossi Z M, Koenig A B, Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.
[3] 杨楠, 敖娜, 马卓奇, 等. 伴非酒精性脂肪性肝病的2型糖尿病患者血清miR-33水平的变化[J]. 中国医师杂志, 2021, 23(10) : 1501-1505.
[4] 杜雪冰,朱晓东,王红艳,等. 血清CA199、CEA与非酒精性脂肪肝的相关性[J]. 分子诊断与治疗杂志, 2025, 17 (01): 54-57+66.
[5] 王玉洁,覃后继,易廷庄,等.非酒精性脂肪性肝病与相关肝细胞肝癌研究进展[J]. 中国医学创新,2024,21(14):173-178.
[6] Zhou X D, Targher G, Byrne C D, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD[J]. Hepatol Int,2023, 17(4):773-791.
[7] 产松苗, 欧希龙, 孙为豪,等. 南京市梅山社区脂肪肝患病率及其危险因素回顾[J]. 世界华人消化杂志,2016,24(3): 420-425.
[8] Zhou J H,Zhou F,Wang W X,et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020,71(5):1851-1864.
[9] Zheng Y, Xu K, Hu H, et al.Prevalence and incidence of non-alcohol fatty liver disease in chronic hepatitis B population in Southeast China: a community-based study[J]. Front Med (Lausanne), 2021,8:683872.
[10] 杨兴祥,刘玉萍,戴敏,等.成都市健康体检成人非酒精性脂肪肝流行病学研究[J]. 中华健康管理学杂志,2010,4(1):22-24.
[11] Zhu J Z, Zhou Q Y, Wang Y M,et al. Prevalence of fatty liver disease and the economy in China: a systematic review[J]. World J Gastroenterol,2015,21(18):5695-5706.
[12] Ayan M, Barsha P, Debosree G. The pathophysiology and management of NAFDL in post-menopausal women: an updated short review[J]. LIDSEN Publishing Inc, 2023, 7(4): 1-8.
[13] Zhou Y J, Li Y Y, Nie Y Q,et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol,2007,13(47):6419-6424.
[14] Zhong X, Huang D, Chen R,et al. Positive association between insulin resistance and fatty liver disease in psoriasis: evidence from a cross-sectional study[J]. Front Immunol,2024;15:1388967.
[15] Dong W, Gong Y, Zhao J, et al. A combined analysis of TyG index, SII index, and SIRI index: positive association with CHD risk and coronary atherosclerosis severity in patients with NAFLD[J]. Front Endocrinol (Lausanne),2024,14:1281839.
[16] 印磊, 陈钟. Toll样受体4在肝细胞肝癌中的研究进展[J]. 世界华人消化杂志,2016,24(4): 535-541
[17] Sheka A C, Adeyi O, Thompson J, et al. Nonalcoholic Steatohepatitis: a review[J]. JAMA,2020,323(12):1175-1183.
[18] Devi S S .2.02 - Structure and function of hepatic parenchymal cells[M]. Comprehensive Toxicology (Third Edition), 2018: 10-28.
[19] 张丽慧,刘鸣昊,赵文霞.脂毒性在非酒精性脂肪性肝病发生发展中的作用[J]. 临床肝胆病杂志2021, 37(2): 463-466.
[20] 郅果果,穆杰,邵冰杰,等.脂毒性在非酒精性脂肪性肝炎中的作用机制[J]. 临床肝胆病杂志, 2023, 39(7): 1681-1686.
[21] Zhao J, Yu L, Sun K, et al. Nonlinear relationship between systemic immune-inflammation and hepatic steatosis: a population-based study in China[J]. J Inflamm Res. 2024,17:711-720.
[22] Wang W, Guo X L, Qiu X P, et al. Systemic immune-inflammation index mediates the association between metabolic dysfunction-associated fatty liver disease and sub-clinical carotid atherosclerosis: a mediation analysis[J]. Front Endocrinol (Lausanne), 2024;15:1406793.
[23] Song Y, Guo W, Li Z, et al. Systemic immune-inflammation index is associated with hepatic steatosis: evidence from NHANES 2015-2018[J]. Front Immunol,2022,13:1058779.
[24] Sun W, Fang Y, Zhou B, et al. The association of systemic inflammatory biomarkers with non-alcoholic fatty liver disease: a large population-based cross-sectional study[J]. Elsevier Bv, 2023,37:102536.
[25] Varsha K K, Narisetty V, Brar K K, et al. Bioactive metabolites in functional and fermented foods and their role as immunity booster and anti-viral innate mechanisms[J]. Journal of food science and technology,2022,60(9):1-10.
[26] Menni A E, Tzikos G, Fyntanidou B, et al.The effect of probiotics on the prognostication of the neutrophil-to-lymphocyte ratio in severe multi-trauma patients[J]. J Pers Med,2024,14(4):419.